Bitte aktiviere Javascript und schalte etwaige Werbeblocker ab

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

DGAP-News: EVOTEC UND BRISTOL-MYERS SQUIBB ERWEITEREN IPSC-ALLIANZ: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC UND BRISTOL-MYERS SQUIBB ERWEITEREN IPSC-ALLIANZ

DGAP-News: EVOTEC UND BRISTOL-MYERS SQUIBB ERWEITEREN IPSC-ALLIANZ

0

DGAP-News: EVOTEC AND BRISTOL-MYERS SQUIBB EXPAND IPSC COLLABORATION: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC AND BRISTOL-MYERS SQUIBB EXPAND IPSC COLLABORATION

DGAP-News: EVOTEC AND BRISTOL-MYERS SQUIBB EXPAND IPSC COLLABORATION

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

Correction of a release from 02.01.2020, 09:55 CET/CEST - Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

DGAP-News: EVOTEC NIMMT AN INVESTORENKONFERENZEN TEIL: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC NIMMT AN INVESTORENKONFERENZEN TEIL

DGAP-News: EVOTEC NIMMT AN INVESTORENKONFERENZEN TEIL

0

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

0

Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

Sartorius Stedim Biotech SA: ANNUAL REPORT OF THE LIQUIDITY CONTRACT WITH THE STOCKBROKER COMPANY GILBERT DUPONT

0

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein

DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein

0

DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA

DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA

0

DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA

DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA

0

DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein

DGAP-News: MorphoSys reicht Zulassungsantrag für Tafasitamab zur Behandlung von R/R DLBCL bei der FDA ein

0

DGAP-News: MorphoSys startet Phase 1-Studie mit Tafasitamab als Erstlinienbehandlung in DLBCL

DGAP-News: MorphoSys startet Phase 1-Studie mit Tafasitamab als Erstlinienbehandlung in DLBCL

0